Sustained Health-Related Quality of Life (HRQoL) Improvement in Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib/Melphalan/Prednisone Versus Melphalan/Prednisone: Results From the VISTA Trial.

被引：0

作者：

Dhawan, Ravinder ^{[1
]}

Robinson, Don, Jr. ^{[1
]}

Meunier, Juliette ^{[2
]}

Regnault, Antoine ^{[2
]}

Rosa, Kathleen ^{[3
]}

Cakana, Andrew Z. ^{[4
]}

van de Velde, Helgi ^{[5
]}

Richardson, Paul G. ^{[6
]}

San Miguel, Jesus F. ^{[7
]}

机构：

[1] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA

[2] Mapi Values, Lyon, France

[3] Mapi Values, Boston, MA USA

[4] Johnson & Johnson Pharmaceut Res & Dev, High Wycombe, Bucks, England

[5] Johnson & Johnson Pharmaceut Res & Dev, Bonaire, Neth Antilles

[6] Dana Farber Canc Inst, Boston, MA 02115 USA

[7] Hosp Univ Salamanca, Hematol Serv, Salamanca, Spain

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：747 / 747

页数：1

共 50 条

[1] IMPACT OF TUMOR RESPONSE ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH VELCADE/MELPHALAN/PREDNISONE (V-MP): RESULTS FROM THE VISTA TRIAL
Meunier, J.
Regnault, A.
Robinson, D.
Rosa, K.
San Miguel, J. F.
van de Velde, H.
Richardson, P. G.
Cakana, A.
Dhawan, R.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A284 - A284
[2] Effect of Thalidomide with Melphalan and Prednisone on Health-Related Quality of Life (HRQoL) in Elderly Patients with Newly Diagnosed Multiple Myeloma: A Prospective Analysis In a Randomized Trial
Verelst, S.
Termorshuizen, F.
Uyl-de Groot, C.
Schaafsma, M. R.
Ammerlaan, R.
Wittebol, S.
Sinnige, H.
Zweegman, S.
Kooy, M. van Marwijk
van der Griend, R.
Lokhorst, H.
Sonneveld, P.
Wijermans, P.
[J]. BLOOD, 2010, 116 (21) : 1225 - 1226
[3] Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial
Verelst, Silvia G. R.
Termorshuizen, F.
Uyl-de Groot, C. A.
Schaafsma, M. R.
Ammerlaan, A. H. M.
Wittebol, S.
Sinnige, H. A. M.
Zweegman, S.
Kooy, M. van Marwijk
van der Griend, R.
Lokhorst, H. M.
Sonneveld, P.
Wijermans, P. W.
[J]. ANNALS OF HEMATOLOGY, 2011, 90 (12) : 1427 - 1439
[4] Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial
Silvia G. R. Verelst
F. Termorshuizen
C. A. Uyl-de Groot
M. R. Schaafsma
A. H. M. Ammerlaan
S. Wittebol
H. A. M. Sinnige
S. Zweegman
M. van Marwijk Kooy
R. van der Griend
H. M. Lokhorst
P. Sonneveld
P. W. Wijermans
[J]. Annals of Hematology, 2011, 90 : 1427 - 1439
[5] Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in TransplantIneligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone
Hou, Jian
Fu, Weijun
Bang, Soo-Mee
Huang, Honghui
Kim, Kihyun
Li, Wei
An, Gang
Lee, Je-Jung
Cai, Zhen
Jin, Jie
Wang, Yafei
Chim, C. S.
Rodriguez-Otero, Paula
Dimopoulos, Meletios A.
Fujisaki, Tomoaki
Lee, Jae Hoon
Wroblewski, Susan
Carson, Robin
Qi, Ming
Wang, Jianping
Song, Yang
Bin Jia
Yang, Xue
Liu, Wenyu
Li, Yunan
Zhang, Renyi
Wang, Jianxiang
[J]. BLOOD, 2021, 138
[6] Impact of interferon on the health-related quality of life of multiple myeloma patients treated with melphalan and prednisone
Wisloff, F
Hjorth, M
Westin, J
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 1152 - 1152
[7] Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone in Newly Diagnosed Multiple Myeloma
Miguel, Jesus F. San
Schlag, Rudolf
Khuageva, Nuriet K.
Dimopoulos, Meletios A.
Shpilberg, Ofer
Kropff, Martin H.
Spicka, Ivan
Petrucci, Maria Teresa
Palumbo, Antonio
Samoilova, Olga S.
Dmoszynska, Anna
Abdulkadyrov, Kudrat M.
Schots, Rik
Jiang, Bin
Mateos, Maria-Victoria
Anderson, Kenneth C.
Esseltine, Dixie-Lee
Liu, Kevin
Cakana, Andrew
van de Velde, Helgi
Richardson, Paul
[J]. BLOOD, 2008, 112 (11) : 242 - 242
[8] Subcutaneous Bortezomib, Melphalan and Prednisone in Elderly Newly Diagnosed Multiple Myeloma Patients
Herbaux, Charles
Joao, Cristina M.
Plocque, Alexia
Richez, Valentine
Gay, Francesca
Renaud, Loic
Legros, Laurence
Garderet, Laurent
Ikhlef, Souhila
Pegourie, Brigitte
Escoffre-Barbe, Martine
Royer, Bruno
Voillat, Laurent
Hulin, Cyrille
Banos, Anne
Voog, Eric G.
Karlin, Lionel
Stoppa, Anne-Marie
Benboubker, Lotfi
Zweegman, Sonja
De Jongh, Eva
Abildgaard, Niels
Le Du, Katell
Jurczyszyn, Artur J.
Moreau, Philippe
Facon, Thierry
Caillot, Denis
Terpos, Evangelos
Leleu, Xavier
[J]. BLOOD, 2014, 124 (21)
[9] Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone
Mateos, Maria-Victoria
Cavo, Michele
Blade, Joan
Dimopoulos, Meletios A.
Suzuki, Kenshi
Jakubowiak, Andrzej
Knop, Stefan
Doyen, Chantal
Lucio, Paulo
Nagy, Zsolt
Pour, Ludek
Cook, Mark
Grosicki, Sebastian
Crepaldi, Andre H.
Liberati, Anna Marina
Campbell, Philip
Shelekhova, Tatiana
Yoon, Sung-Soo
Iosava, Genadi
Fujisaki, Tomoaki
Garg, Mamta
Krevvata, Maria
Wang, Jianping
Kudva, Anupa
Ukropec, Jon
Wroblewski, Susan
Kobos, Rachel
San-Miguel, Jesus
[J]. BLOOD, 2019, 134
[10] Efficacy and safety of Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) versus Bortezomib, Melphalan, and Prednisone (VMP) in Chinese patients with newly diagnosed Multiple Myeloma: OCTANS
Fu, Weijun
Huang, Honghui
Li, Wei
An, Gang
Cai, Zhen
Jin, Jie
Wang, Yafei
Chim, Chor Sang
Qi, Ming
Wang, Jianping
Song, Yang
Jia, Bin
Yang, Xue
Liu, Wenyu
Li, Yunan
Zhang, Renyi
Hou, Jian
Wang, Jianxiang
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S125 - S125

← 1 2 3 4 5 →